Reply to the correspondence to the “Guideline for acute therapy and management of anaphylaxis”

The authors of the guidelines [1] thank Drs. Rudolph and Fischer (InfectoPharm) for their comments [2] and would like to respond as follows:

1. It is correct that the administration of 2 ml of a 1-mg/ml adrenaline solution in inhaled form, as stated in Tables 6 and 7, does not conform to the drug approval for ampoules available on the market. The authors regret that they did not make explicit reference to this „off-label“ status. Possible side effects due to sulphite content should be of minor importance in an emergency setting. However, the alternative mentioned, i.e., inhaling with InfectoKrupp Inhal®, is similarly not approved for use in anaphylaxis.
2. While it is also correct that an adrenaline solution is available for use in a nebulizer, this preparation is not – as mentioned above – approved for the treatment of anaphylaxis. The above-mentioned study by Breuer et al. [3] was commissioned by the manufacturer as a preclinical pilot study in eight healthy adults that used a nebulizer system of this kind. Said study had serum concentration as its sole endpoint and did not investigate the clinical effect of adrenaline. Thus, it is not possible to draw any valid conclusions on the efficacy of this method in the treatment of anaphylaxis. Furthermore, the preparation appears to be difficult to handle in an emergency setting to the extent that, following intense discussion, the guideline group decided against recommending it for this indication.

In summary, it is correct that the off-label use of medicinal products should be explicitly mentioned in guidelines. This omission is hereby rectified. We express our thanks to Drs. Rudolph and Fischer for drawing our attention to this point. The recommen-

dation regarding the described treatment procedure remains otherwise unchanged.

Prof. Dr. Dr. Johannes Ring
(Guideline coordinator)
Klinikum rechts der Isar
Technische Universität Munich
Biedersteiner Straße 29
80802 Munich, Germany
E-Mail: johannes.ring@tum.de

Cite this as

Ring J. Reply to the correspondence to the “Guideline for acute therapy and management of anaphylaxis”. *Allergo J Int* 2015;24:45
DOI: 10.1007/s40629-015-0040-x

References

1. Ring J, Beyer K, Biedermann T, Bircher A, Duda D, Fischer J et al. Guideline for acute therapy and management of anaphylaxis. S2 Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB). *Allergo J Int* 2014; 23: 96–112
2. Rudolph M, Fischer M. Correspondence to “Guideline for acute therapy and management of anaphylaxis”. *Allergo J Int* 2015;24:44
3. Breuer C, Wachall B, Gerbeth K, Abdel-Tawab M, Fuhr U. Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. *Eur J Clin Pharmacol* 2013;69:1303–10

German version
www.springer-medizin.de/allergo-Journal